key: cord-1030338-p268zv5u
authors: Tamartash, Zahra; Javinani, Ali; Gharibdoost, Farhad; Atef Yekta, Reza; Mohammadzadegan, Amirmohammad; Kavosi, Hoda
title: The clinical course of COVID-19 in systemic sclerosis patients, report from 150 patients
date: 2021-04-16
journal: Intern Emerg Med
DOI: 10.1007/s11739-021-02727-7
sha: 5a648bb5c84bd9353e459536dcb7ca43cec6971c
doc_id: 1030338
cord_uid: p268zv5u

nan

Of 150 patients with SSc (95.3% female, the mean age of 44.4 ± 14.5 years), 14 had symptoms consistent with COVID-19. Seven of 14 (50%) had a positive Polymerase Chain Reaction (PCR) test for SARS-CoV-2 by rhinopharyngeal sampling, two (14.2%) had findings suggestive of COVID-19 in their chest Computed Tomography (CT) scans, and five (35.7%) had the characteristic clinical manifestations of the disease. The immunosuppressive regimen of these 14 patients included prednisolone in 85.7% of the patients, mycophenolate mofetil in 57.1%, azathioprine in 21.4%, and rituximab in 7.1% (clinical, laboratory, and imaging findings are listed in Table 1 ).

In addition, 11 patients (78.5%) had mild symptoms and were treated as outpatients, while 3 (21.4%) were hospitalized in non-ICU wards due to hypoxemia. There was no mortality. The medical treatment for COVID-19 included hydroxychloroquine for 7 patients (50%), azithromycin for 5 patients (35.7%), and Interferon-alpha 1 beta and colchicine for 2 patients.

According to our findings, 6% of the patients had a positive PCR test for SARS-CoV-2. A previous study in northern Italy reported 65 (4.26%) PCR-positive cases of COVID-19 in 1525 rheumatologic patients [4] . Moreover, the incidence of COVID-19 was 15% in a Chinese population of rheumatologic patients treated with biologic agents, all of whom had mild symptoms [5] . In a cohort of SSc patients in Italy, there were only 2 confirmed COVID-19 cases (out of 526), which is compatible with other studies. The lower incidence of COVID-19 in these studies may be due to the strict national obligations and extensive serological testing in the national surveys [6] .

Of 14 patients with suspected or confirmed COVID-19, eight (57.1%) were suffering from SSc-related interstitial lung disease. However, only three (21.4%) developed hypoxemia leading to hospitalization, while the other patients had mild disease without respiratory complications and were treated as outpatients. Compatible with our findings, studies [7] . In the mentioned cohort in Italy, which included 526 patients with limited or diffuse SSc with almost equal numbers (270 and 256, respectively), 45% had interstitial lung disease. Of these patients, only 2 suffered COVID-19 induced pneumonia and one of them had died [6] . We hypothesized that the relatively low prevalence of COVID-19 in our study population was related to the strict health instructions given to our patients. Since the first days of the COVID-19 pandemic in Iran, SSc patients with access to the Internet and social media were instructed to wear face masks, strictly adhere to hand hygiene protocols, and avoid unnecessary personal communication. Patients with a medical emergency were visited by a rheumatologist via telemedicine.

In conclusion, SSc patients have a COVID-19 similar clinical presentation to the normal population. However, further studies are needed to elucidate the puzzling effects 

The authors declare that there is not any conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent In addition, informed consent was obtained from all individual participants included in the study.

COVID-19: the new challenge for rheumatologists. First update

Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers

COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study

Clinical characteristics of coronavirus disease 2019 in China

Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis

Are my patients with rheumatic diseases at higher risk of COVID-19?